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Stereotactic radiosurgery (SRS) is an alternative to surgery or whole brain radiotherapy for 
control of single or multiple brain metastases in patients with breast cancer.   To date, there is 
no clear consensus on factors that might predict overall survival (OS) following SRS.  
 
Methods:  
Retrospective analysis of consecutive patients with breast cancer and brain metastases, 
considered suitable for SRS by the regional neuro-oncology multi-disciplinary team (MDT). 
All patients were treated at a single NHS centre. 
 
Results:  
91 patients received SRS between 2013 and 2017, of whom 15 (16.5%) were alive at the time 
of analysis.  Median OS post SRS was 15.7 months (IQR 7.7 – 23.8months) with no 
significant effect of age on survival (67 patients ≤65yr, 16.3 months; 26 patients >65yr, 11.4 
months, p=0.129).  Primary tumour receptor status was an important determinant of outcome:  
31 Oestrogen receptor positive (ER+)/Human epidermal growth factor receptor 2 (HER2) 
negative patients had a median OS of 13.8 months, 14 ER+/HER2+ patients had a median OS 
of 21.4 months, 30 ER-/HER2+ patients had a median OS of 20.4 months and 16 patients 
with triple negative breast cancer (TNBC) had a median OS of 8.5 months.  A larger total 
volume of tumour treated (>10cm3), but not the number of individual metastases treated, was 
associated with worse survival (p=0.0002) in this series.  Patients with stable extra-cranial 
disease at the time of SRS had improved OS compared to those with progressive extra-cranial 
disease (30 patients stable extra-cranial disease OS=20.1 months v 33 patients progressive 
extra-cranial disease OS=11.4 months; p=0.0011).  17 patients had no extra-cranial disease at 
the time of SRS with a median OS of 13.1 months. 
 
Conclusions:  
This single centre series of consecutive patients with brain metastases from breast cancer, 
treated with SRS, had a similar OS compared to previous studies of SRS.  TNBC and 
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ER+/HER2- histology, metastatic volumes >10cm3 and progressive extra-cranial disease at 
time of SRS are associated with worse survival.  
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Breast cancer is commonly associated with the development of brain metastases (BM) with 
historical post-mortem studies suggesting BM may occur in up to 30% of patients [1, 2]. 
Survival is typically poor with one study reporting a median survival of 16 months after 
developing BM in patients treated with surgery and whole brain radiotherapy [3].   There are 
many factors that may influence both the incidence of BM and survival after developing BM 
including tumour receptor status. A series of 488 patients found those with human epidermal 
growth factor receptor 2 positive (HER2+) or triple negative (TNBC) breast cancer had an 
increased risk of developing BM.  After diagnosis of BM, there was a significant difference in 
the median overall survival (OS) of patients according to receptor subtypes; 7.4 months for 
oestrogen receptor positive (ER+)/HER2- patients, 19.2 months for ER+/HER2+ patients, 7 
months for ER-/HER2+ patients and 4.9 months for TNBC patients, with treatment including 
whole brain radiotherapy (WBRT), surgery or stereotactic radiosurgery (SRS) [4].  
 
Traditionally, treatment for BM has been surgery or WBRT with both modalities associated 
with significant acute and chronic complications.  In a meta-analysis of 742 patients treated 
for BM with surgery followed by WBRT, neurocognitive impairment was seen in 12-28% of 
patients [5]. More targeted treatment with SRS is associated with reduced levels of cognitive 
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decline compared to WBRT (63.5% of patients v 91.7% of patients at 3 months respectively) 
and improved quality of life [6].  In a meta-analysis of 364 patients, SRS alone had a better 
pooled OS compared to WBRT but this was only statistically significant in patients less than 
50 years old [7]. With improvements in systemic therapies for metastatic breast cancer, 
longer survival and reducing the risk of toxicity from treatment of BM is increasingly 
important [8]. 
 
Despite the apparent benefit of SRS there is a paucity of evidence examining patient criteria 
that might influence survival post treatment. The aim of this study was to assess the overall 
survival of breast cancer patients with BM treated with SRS at a single centre and to examine 
factors that might influence survival to help inform future research and clinical practice.   
 
Methods: 
Retrospective data was collected on consecutive breast cancer patients who received SRS for 
BM between November 2013 and August 2017 in a single tertiary NHS oncology centre in 
Bristol, UK. Data was censored on 1/5/19. Patient records were accessed to collect 
demographic and clinical information.  All patients were recommended treatment following 
central discussion by the regional neuro-oncology MDT and review with a clinical oncologist. 
 
For each patient, their date of diagnosis, receptor status and initial staging, split into local only, 
nodal or metastatic disease was collected.  The date of BM diagnosis and extra-cranial disease 
status was accessed from The InSight PACS Medical Imaging system (Insignia medical 
systems, Basingstoke, UK).  SRS treatment plans were reviewed for number and volume of 
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metastases.  The intra and extra-cranial disease status at time of death or last clinical review, 
as well as current patient status was obtained from patient records and imaging.  Regional 
neuro-oncology MDT outcomes were reviewed to corroborate patient and treatment data.  The 
number of lines and setting of systemic treatments given both before and after SRS treatment 
was collected where available. 
 
Gamma knife radiosurgery was delivered using the Leksell Gamma Knife Icon with its inbuilt 
high-definition motion management system.  Patients were immobilised with fixed frames.  
SRS treatment was planned from gadolinium contrasted T1 and T2 weighted MRI imaging, 
performed from the base ring to the vertex at 1-1.5mm slice thickness.  Any discrepancy or 
distortion on the MRI images was checked via CT imaging for co-registration.  The planned 
treatment volume was defined as the gross tumour volume on MRI imaging. Dose was 
prescribed according to tumour diameter:  <2cm = 24 Gray (Gy), 2-3cm 22Gy, 3-4cm 20Gy.  
In single metastases where patients had not received whole brain therapy, doses were increased 
by 2Gy. 192 cobalt-60 sources delivered multiple narrow low energy beams of radiation.  
Patient motion was detected on any movement of >0.5mm and an automatic stop was inserted 
at 1.5mm and with consistent movements of >0.7mm a second stereotactic cone beam CT was 
used to reset the treatment plan [9]. 
 
Univariate statistical analysis was undertaken on survival data, using Mann-Whitney U tests to 
look for significance between groups using GraphPad Prism (v 8.0).  Kaplan-Meier survival 
curves were generated to compare different groups; significance was checked with log-rank 
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91 patients with a median age of 57 years (range 23-78) received SRS, of whom 15 patients 
(16.5%) were alive at the date of analysis. Median OS for all patients was 15.7 months from 
time of SRS.  The tumour receptor status was:  ER+/HER2- 31 patients (33.3%), ER+/HER2+ 
14 patients (15.1%), ER-/HER2+ 30 patients (32.2%), Triple negative 16 patients (17.2%), 
Unknown 2 patients (2.2%).  70/87 patients had extra-cranial disease at the time of SRS, in 7 
of these patients the status of the extra-cranial disease was unknown, extra-cranial disease 
status was not known in 4 patients.  Patients had a median of 2 brain metastases treated 
(Interquartile range (IQR) 1-4) and a median volume of 3.8cm3 treated (IQR 1.0cm3-8.2cm3).  
Patient characteristics are summarised in Tables 1 and 2.  Complete systemic treatment 
histories were available for 60/91 (65.9%) patients (Table 1).  The majority of patients (62%) 
received at least one line of chemotherapy in the metastatic setting prior to SRS treatment.  38 
patients received chemotherapy after SRS treatment, with most (76.3%) receiving one line, 
18.4% of patients received two lines and 5.3% of patients received 3 lines.   
 
Receptor profile:  
There was a difference in the median time to the development of BM based on the primary 
tumour receptor profile: ER+/HER2- 79.3 months, ER+/HER2+ 68.6 months, ER-/HER2+ 
39.3 months and TNBC 23.8 months.   This reached statistical significance comparing TNBC 
and ER+/HER2- (p=0.036) and TNBC and ER+/HER2+ (p=0.045) (Table 3). The median OS 
following SRS was ER+/HER2- 13.8 months, ER+/HER2+ 21.4 months, ER-/HER2+ 20.4 
months and TNBC 8.5 months. Patients with TNBC had a worse prognosis compared to all 
other subgroups (TNBC v ER+/HER2- p=0.025, TNBC v ER+/HER2+ p=0.0011, TNBC v 
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ER-/HER2+ p=<0.001).  ER+/HER2- pts had a poorer survival than ER+/HER2+ p=0.0499 
and ER-/HER2+ p=<0.0242.  (Table 3 and Figure 1).  
 
Control of extra-cranial disease and age at the time of SRS:  
At the time of SRS, 17 patients were known to have no extracranial disease (Median OS 13.1 
months). When present, stable extracranial disease (stable disease or partial response on latest 
imaging) was associated with a significantly improved OS (33 pts stable extracranial disease 
OS=20.1 months, 30 patients progressive extracranial disease OS=11.4 months; p=0.0011) 
(Table 4 and Figure 2). 66 patients were under 65 with a median OS 16.3 months whereas 25 
patients were over 65 with a median OS 11.4 months) (p=0.129) (Table 4).   
 
Overall survival by number of lesions treated and volume of treatment: 
During SRS, 39 patients had 1 lesion treated (OS 18.1 months), 33 patients 2-5 lesions treated 
(OS 10.1 months), 19 patients ≥6 lesions (OS 18.3 months) with no significant difference in 
OS between any category (Table 4).  In contrast, the total volume of disease treated affected 
overall survival; tumours totalling <1cm3 24 patients with median OS of 22.6 months, 1.1-5cm3 
29 patients OS of 16.3 months, 5.1-10cm3 23 patients OS of 15.7 months and >10.1cm3 15 
patients OS of 9.2 months.  A total volume >10cm3 had a significant adverse effect on OS 
compared to all other categories (<1cm3 p=<0.0001, 1.1-5cm3 p= 0.0015 and 5.1-10cm3 
p=0.0023) (Table 4, Figure 3). 
 
For 57/76 patients who had died at the time of analysis the disease status was known.  38.6% 
had progressive extra-cranial disease only, 26.3% had progressive intra-cranial disease only, 
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This single centre retrospective series, reporting the outcome from treating brain metastases 
from breast cancer with SRS in a large tertiary referral centre in the UK found a median overall 
survival of 15.7 months which is consistent with other published retrospective studies [10-23].   
 
Previous publications have considered multiple factors that might predict overall survival, 
including patient age at time of SRS, Karnofsky Performance Score, tumour receptor profile 
and the volume and number of brain metastases treated. The results of these studies are 
summarised in Table 5 [10-23].  Most have shown that TNBC has a lower OS compared to 
other receptor subtypes, however, the link between the total number and/or volume of brain 
metastases and overall survival following SRS is less clear.  NHS England recommends that 
SRS should only be given with multidisciplinary team approval, a Karnofsky Performance 
Score >70, a maximum disease volume of 20cm3 and a predicted life expectancy of at least 6 
months [24]. This is line with the American Society for Radiation Oncology guidelines which 
recommends use of SRS for single lesions <3cm in diameter in patients with a good prognosis 
[25].  
 
Results from our series are consistent with a previous study of 2441 patients which suggested 
that ER+ patients develop BM later in their disease course with a median time to development 
of BM of 63.5 months compared to 30 months (HER2+) and 22 months (TNBC) [26].  Our 
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study suggests not just ER+HER2- (79.3 months) but also ER+/HER2+ (68.6 months) develop 
BM later in their disease course. HER2+ patients will have received anti-HER2 therapies, often 
in both the (neo)adjuvant and metastatic setting which may have modified the time frame for 
development of BM. The longer time period to development of BM in ER+ breast cancers may 
be secondary to a more indolent disease course as well as the efficacy of anti-oestrogen 
therapies as shown in a meta-analysis of 62923 ER+ breast cancer patients where recurrent 
disease occurred at a steady rate between 5 and 20 years following 5 years of adjuvant 
endocrine therapy [27].   
 
Compared to publications that have reported OS following the development of BM by receptor 
subtypes, where patients were mostly treated with WBRT, our study showed better OS across 
all receptor subtypes [10, 28, 29]. The improvement in OS is likely a result of careful patient 
selection, increased experience with SRS planning and implementation, improved systemic 
therapies and an increasing tendency to perform early scans allowing patients to be treated with 
smaller cerebral metastatic volume.  
  
Patients with metastatic volumes totalling <1cm3 had a median OS of 22.6 months, falling to 
9.2 months for those with >10.1cm3 treated.  Although life expectancy for all groups was 
greater than six months as per NHS guidance, the reduced survival of patients with tumour 
volumes >10cm3 may be due to higher rates of local recurrence seen after SRS alone ( Meta-
analysis of 364 patients treated for 1 to 4 brain metastases showed local recurrence rates of; 
27% in patients treated with SRS alone v 12% in patients treated with both SRS and WBRT 
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Whilst the age of patients treated did not affect survival in our series, the presence and control 
of extra-cranial disease both at time of SRS and during follow up was important.  Surprisingly, 
patients with disease limited to the brain did not have better survival than patients with 
controlled extra-cranial disease (13.1mths v 20.1mths).  However, there was a higher 
percentage of TNBC patients (35.3%) in this cohort perhaps suggesting a propensity for TNBC 
to first metastasise to the brain compared to other receptor subtypes with further research 
needed to evaluate whether earlier systemic treatment could improve survival.. For patients 
with HER2+ breast cancer with intracranial disease as the only site of metastases the recently 
updated ESMO advanced breast cancer guidelines do not currently recommend the addition of 
chemotherapy to SRS [30].  Of the patients with extra-cranial disease at the time of SRS, those 
with controlled extra-cranial disease had significantly better OS than patients who had 
progressive disease both intra and extra-cranially.  This supports ESMO and NICE guidelines 
which recommend systemic therapy should not be altered post-SRS in HER2+ patients with 
stable extra-cranial disease [30, 31].  Although patients with progressive systemic disease at 
the time of SRS had worse outcomes, the median OS for these patients is still 11.4 months and 
therefore this series suggests that in selected patients this should not be used in isolation as a 
reason to omit SRS.  Patient numbers were too few to accurately assess the effect of 
chemotherapy after SRS. 
 
Whilst results from this series must be interpreted with caution this study adds to the limited 
published literature on SRS for brain metastases secondary to breast cancer and highlights the 
improved OS in this patient cohort. The factors identified that predict survival can be used to 
help inform both patient selection and discussions between clinicians and patients about the 
potential benefits and risks of SRS. Future prospective, multi-centre studies with greater patient 
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numbers, assessment of SRS technique, assessment of systemic anti-cancer therapy post-SRS 
and potential randomisation for patients with brain only disease between starting systemic 
therapy and SRS versus SRS alone should be designed to help in the development of more 
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